Uzbekistan Medical Device Labeling Language Requirements
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The language rules for Uzbek labels and instructions for use operate at two levels. At the user-facing level, Uzbek (the state language) is mandatory, and foreign manufacturers may additionally provide Russian or English. At the technical dossier and power of attorney level, a separate set of rules applies: where a power of attorney is drawn up in a language other than Uzbek, Karakalpak, Russian or English, the accuracy of its Uzbek translation must be notarized, under registered order No. 3888, applicable from October 8, 2026. Mixing the two levels is a frequent cause of document rework: labels prepared in English only are returned, while technical files prepared in Russian only may stall at the notarization stage. The two levels also differ in scope beyond labeling: item 2.14 of Resolution No. 738 requires the state language translation of test results and conclusions for stability study reports of products with a shelf life, and item 2.19 and item 2.20 fix the language of labeling and instructions for use. Language capability additionally extends into the post-market phase, where product cards in the digital marking system, representative contact details and local clinical feedback all operate in the state language environment. Planning both language tracks at the start of the project, with a defined translation and notarization sequence, is the reliable way to avoid rework at the review stage.
2. Legal basis
| Regulation | Number | Date | Provisions |
|---|---|---|---|
| Cabinet of Ministers Resolution on Approving the Regulation on State Registration of Medicines and Medical Devices and the Issuance of Registration Certificates | No. 738 | Adopted November 24, 2025, effective February 26, 2026 | Item 2.19: labeling and package information (state language text; foreign manufacturers may additionally use Russian or English); Item 2.20: instructions for use (state language; foreign manufacturers may additionally use Russian or English) |
| Cabinet of Ministers Resolution on Approving the Regulation on State Registration of Medicines and Medical Devices and the Issuance of Registration Certificates | No. 738 | Adopted November 24, 2025 | Item 2.14: stability study report for products with a shelf life, with the state language translation of test results and conclusions attached |
| Rules for Preparing Medical Device Registration Dossiers (registered order) | No. 3888 | Registered July 2026, effective October 8, 2026 | Where the power of attorney of a foreign manufacturer is drawn up in a language other than Uzbek, Karakalpak, Russian or English, the accuracy of its Uzbek translation must be notarized |
| Presidential Decree (digital marking codes) | No. UP-296 | October 6, 2025 | The digital marking system fully effective from March 1, 2026 |
3. Expert insights
Insight one: Russian is the working language of technical communication in practice, but the state language is the compliance floor. The wording of Resolution No. 738 is state language text, with Russian or English additionally available to foreign manufacturers. Russian can therefore be one of the languages provided, but it cannot replace Uzbek. In multilingual packaging, the usability of the Uzbek text, rather than its mere presence, is the review point: instructions for use with visible machine translation marks are sent back for rework at the label review stage. A professionally translated Uzbek text with a stable terminology base is the safe position.
Insight two: registered order No. 3888 pinned the notarization obligation to the specific language. Where a power of attorney is drawn up in Chinese, an Uzbek translation is required and the accuracy of the translation must be notarized. This requirement is additive to the general notarization and legalization chain, not a substitute for it. When planning the authentication workflow, companies must schedule translation notarization as a discrete step; otherwise a document can complete apostille and then stall at translation notarization, wasting the lead time already invested in the legalization chain.
Insight three: the translation requirement for stability study reports applies at the level of results and conclusions. Item 2.14 requires the stability study report of a product with a shelf life to carry the state language translation of the test results and conclusions, not a full translation. This distinction materially reduces translation cost: the company translates the concluding content, while the raw data tables remain in the original language. The saving is only available if the scope of translation is defined before the dossier is assembled, not negotiated during a deficiency response.
Insight four: language requirements extend into the post-market phase. Product card information under the digital marking system, representative contact details in the instructions for use and local clinical use feedback in post-market surveillance all operate in the state language environment. Language capability is therefore a criterion in representative selection, not a one-time task of the document preparation phase, and it determines how effectively field feedback and regulator queries can be handled after the certificate is issued.
4. Practical recommendations
- Prepare a separate label and instructions language list and a separate dossier language list under the two-level rules; do not share one table between them.
- In the power of attorney authentication workflow, schedule Uzbek translation notarization as a discrete step placed before the apostille.
- Translate only the test results and conclusions of stability study reports and keep the raw data in the original language, to control translation cost.
- Have the Uzbek text of instructions for use and labels produced by translators with a medical background and maintain an internal terminology glossary.
- List state language handling capability as an evaluation criterion when selecting the representative, for post-market communication and feedback collection.
5. Verification checklist
- □ Uzbek text has been provided for labels and instructions for use
- □ Russian or English text has been additionally provided by the foreign manufacturer
- □ The stability study report of the product with a shelf life carries the state language translation of test results and conclusions
- □ The power of attorney drawn up in Chinese has completed notarization of the accuracy of its Uzbek translation
- □ The sequence of translation notarization and apostille or consular legalization has been scheduled
- □ The representative has state language capability to support post-market communication
Regulatory information verified as of October 29, 2026.
GRZAN provides registration support in Uzbekistan for manufacturers, importers and authorized representatives. For assistance with language requirements and dossier preparation, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us